Kamada logo

KamadaNASDAQ: KMDA

Profile

Sector:

Healthcare

Country:

Israel

IPO:

31 May 2013

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$339.78 M
-9%vs. 3y high
61%vs. sector
-70%vs. 3y high
36%vs. sector
-54%vs. 3y high
46%vs. sector
-27%vs. 3y high
40%vs. sector

Price

after hours | Tue, 19 Nov 2024 21:00:09 GMT
$5.91-$0.09(-1.49%)

Dividend

No data over the past 3 years
$41.74 M$149.87 M
$41.74 M$3.86 M

Analysts recommendations

Institutional Ownership

KMDA Latest News

Kamada Ltd. (KMDA) Q3 2024 Earnings Call Transcript
seekingalpha.com13 November 2024 Sentiment: NEUTRAL

Call Start: 08:30 January 1, 0000 9:52 AM ET Kamada Ltd. (NASDAQ:KMDA ) Q3 2024 Earnings Conference Call November 13, 2024, 08:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Greetings, and welcome to the Kamada Ltd.

Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston
globenewswire.com23 September 2024 Sentiment: POSITIVE

REHOVOT, Israel and HOBOKEN, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its plasma collection operations with the opening of a new plasma collection center in Houston, TX. The new 12,000 square foot center is operated by Kamada's wholly owned subsidiary, Kamada Plasma, and is planned to support over 50 donor beds with an estimated total collection capacity of approximately 50,000 liters annually.

Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript
seekingalpha.com14 August 2024 Sentiment: NEUTRAL

Kamada Ltd. (NASDAQ:KMDA ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Troy Williams - LifeSci Advisors Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Greetings, and welcome to Kamada Limited Second Quarter 2024 Earnings Conference Call.

Kamada Ltd. (KMDA) Q4 2023 Earnings Call Transcript
Seeking Alpha06 March 2024 Sentiment: POSITIVE

Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Results Earnings Conference Call March 6, 2024 8:30 AM ET

Kamada: Kedrion Deal Locks In Growth
Seeking Alpha08 December 2023 Sentiment: POSITIVE

Kamada is a profitable specialty plasma company with a strong balance sheet and significant capital available for investment. The company has announced an expanded commercial agreement for its anti-rabies drug Kedrab including a minimum revenue guarantee for the next four years. The new deal significantly derisks the Kamada investment case by locking in growth for one of the company's largest revenue streams.

Kamada: Deep Dive Following FIMI Placement, Rate Buy
Seeking Alpha21 June 2023 Sentiment: POSITIVE

Kamada Ltd. has potential catalysts for growth, capital attraction and regulatory tailwinds. The company's valuation appears attractive, with forward estimates suggesting a possible re-rating. Key risks center around the investment in 2x new manufacturing facilities in its Israeli footprint.

Kamada Ltd. (KMDA) Q1 2023 Earnings Call Transcript
Seeking Alpha24 May 2023 Sentiment: NEUTRAL

Kamada Ltd. (NASDAQ:KMDA ) Q1 2023 Results Earnings Conference Call May 24, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors, LLC Amir London - Chief Executive Officer Conference Call Participants David Bautz - Zacks Small Cap Research Operator Greetings and welcome to the Kamada Ltd.

Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023
GlobeNewsWire17 May 2023 Sentiment: NEUTRAL

REHOVOT, Israel and HOBOKEN, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2023, prior to the open of the U.S. financial markets on Wednesday, May 24, 2023.

What type of business is Kamada?

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

What sector is Kamada in?

Kamada is in the Healthcare sector

What industry is Kamada in?

Kamada is in the Drug Manufacturers - Specialty & Generic industry

What country is Kamada from?

Kamada is headquartered in Israel

When did Kamada go public?

Kamada initial public offering (IPO) was on 31 May 2013

What is Kamada website?

https://www.kamada.com

Is Kamada in the S&P 500?

No, Kamada is not included in the S&P 500 index

Is Kamada in the NASDAQ 100?

No, Kamada is not included in the NASDAQ 100 index

Is Kamada in the Dow Jones?

No, Kamada is not included in the Dow Jones index

When was Kamada the previous earnings report?

No data

When does Kamada earnings report?

Next earnings report date is not announced yet